| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 105.3 | 108.7 | 108.7 |
| Other income | 6.2 | 1.7 | 1.7 |
| Total income | 111.4 | 110.4 | 110.4 |
| Profit before exceptional items & tax | 4.9 | 6.0 | 8.1 |
| Profit before tax | 4.9 | 6.0 | 8.1 |
| Net profit | 3.7 | 4.4 | 4.9 |
| Operating margin | 4.4% | 5.4% | 7.3% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -24.50% |
|---|---|
| Net profit, quarter on quarter | -15.90% |
| Revenue, year on year | -3.10% |
NSE results filing, NSE: ZIMLAB. Figures extracted from the filing.
Zim Laboratories Ltd: key numbers
- Share price
- ₹138.48
- Market cap
- ₹743.1 Cr
- Revenue (annual)
- ₹374.4 Cr
- Net profit (annual)
- ₹5.84 Cr
- P/E (TTM)
- 201.0×Sector 50.4×
- Promoter holding
- 30.36%+0.01% QoQ
- FII holding
- 0.03%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Zim Laboratories Ltd
All →Zim Laboratories Merger & Restructuring Worth ₹1,404,640 Cr
ZIM Laboratories completed incorporation of its wholly-owned Chilean subsidiary, ZIM Laboratories SpA. The LATAM expansion entity is now operational, marking completion of the February 2026 board-approved plan.
- Value
- ₹14,04,640 Cr
Zim Laboratories Merger & Restructuring
ZIM Laboratories Limited incorporated a wholly owned subsidiary, 'ZIM Laboratories SpA', in Chile. This expansion aims to develop its pharmaceutical business in the LATAM region.
Zim Laboratories Acquisition Worth ₹1.56 Cr
ZIM WOS completed a ₹1.56 Crore investment in stepdown ZIM Scientific Office L.L.C., Dubai, fulfilling the board-approved capital plan. The transaction closes the acquisition announced in August 2025.
- Value
- ₹1.56 Cr
Zim Laboratories Merger & Restructuring Worth ₹2.38 Cr
Zim Laboratories confirmed that its subsidiary, ZIM FZE, completed the previously announced AED 9,16,000 investment in its step-down subsidiary, ZIM Scientific Office LLC.
- Value
- ₹2.38 Cr
Zim Laboratories Investor Presentation: Key Takeaways
Zim Laboratories reported 31.2% YoY revenue growth in Q1 FY27, driven by core pharma and exports (84% of income). Strategy focuses on EU-GMP remediation and expanding the innovation-led NIP/OTF portfolio.
- Call
- Guides 32% growth
Zim Laboratories Investor Presentation: Key Takeaways
Q1 FY27 Total Operating Income rose 31.2% YoY to ₹942 Mn. However, EBITDA fell 40% to ₹34 Mn due to utility/employee costs.